Literature DB >> 18336089

An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion.

Colleen A McNaney1, Dieter M Drexler, Serhiy Y Hnatyshyn, Tatyana A Zvyaga, Jay O Knipe, James V Belcastro, Mark Sanders.   

Abstract

An automated process is described for the detailed assessment of the in vitro metabolic stability properties of drug candidates in support of pharmaceutical property profiling. Compounds are incubated with liver microsomes using a robotic liquid handler. Aliquots are taken at various time points, and the resulting samples are quantitatively analyzed by liquid chromatography-mass spectrometry utilizing ion trap mass spectrometers to determine the amount of compound remaining. From these data metabolism rates can be calculated. A high degree of automation is achieved through custom software, which is employed for instrument setup, data processing, and results reporting. The assay setup is highly configurable, allowing for any combination of up to six user-selected time points, variable substrate concentration, and microsomes or other biologically active media. The data, based on relative substrate depletion, affords an estimate of metabolic stability through the calculation of half-life (t(1/2)) and intrinsic clearance, which are used to differentiate and rank order drug leads. In general, t(1/2) is the time necessary for the metabolism, following first-order kinetics, of 50% of the initial compound. Intrinsic clearance is the proportionality constant between rate of metabolism of a compound and its concentration at the enzyme site. Described here is the setup of the assay, and data from assay test compounds are presented.

Mesh:

Substances:

Year:  2008        PMID: 18336089     DOI: 10.1089/adt.2007.103

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  29 in total

1.  Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation.

Authors:  Ariane Wohlfarth; Karl B Scheidweiler; Shaokun Pang; Mingshe Zhu; Marisol Castaneto; Robert Kronstrand; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-09-01       Impact factor: 3.345

2.  Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA.

Authors:  Ariane Wohlfarth; Marisol S Castaneto; Mingshe Zhu; Shaokun Pang; Karl B Scheidweiler; Robert Kronstrand; Marilyn A Huestis
Journal:  AAPS J       Date:  2015-02-28       Impact factor: 4.009

3.  Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.

Authors:  Zilun Hu; Pancras C Wong; Paul J Gilligan; Wei Han; Kumar B Pabbisetty; Jeffrey M Bozarth; Earl J Crain; Timothy Harper; Joseph M Luettgen; Joseph E Myers; Vidhyashankar Ramamurthy; Karen A Rossi; Steven Sheriff; Carol A Watson; Anzi Wei; Joanna J Zheng; Dietmar A Seiffert; Ruth R Wexler; Mimi L Quan
Journal:  ACS Med Chem Lett       Date:  2015-04-08       Impact factor: 4.345

4.  Dialing in on pharmacological features for a therapeutic antioxidant small molecule.

Authors:  Kayla N Green; Kristof Pota; Gyula Tircsó; Réka Anna Gogolák; Olivia Kinsinger; Collin Davda; Kimberly Blain; Samantha M Brewer; Paulina Gonzalez; Hannah M Johnston; Giridhar Akkaraju
Journal:  Dalton Trans       Date:  2019-07-25       Impact factor: 4.390

5.  Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry.

Authors:  Michael G Feasel; Ariane Wohlfarth; John M Nilles; Shaokun Pang; Robert L Kristovich; Marilyn A Huestis
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

6.  Enhancement of the Antioxidant Activity and Neurotherapeutic Features through Pyridol Addition to Tetraazamacrocyclic Molecules.

Authors:  Hannah M Johnston; Kristof Pota; Madalyn M Barnett; Olivia Kinsinger; Paige Braden; Timothy M Schwartz; Emily Hoffer; Nishanth Sadagopan; Nam Nguyen; Yu Yu; Paulina Gonzalez; Gyula Tircsó; Hongli Wu; Giridhar Akkaraju; Michael J Chumley; Kayla N Green
Journal:  Inorg Chem       Date:  2019-11-27       Impact factor: 5.165

7.  In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201).

Authors:  Xingxing Diao; Jeremy Carlier; Mingshe Zhu; Shaokun Pang; Robert Kronstrand; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Forensic Toxicol       Date:  2016-07-06       Impact factor: 4.096

8.  Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18.

Authors:  Richard C Kevin; Timothy W Lefever; Rodney W Snyder; Purvi R Patel; Thomas F Gamage; Timothy R Fennell; Jenny L Wiley; Iain S McGregor; Brian F Thomas
Journal:  Drug Test Anal       Date:  2017-09-28       Impact factor: 3.345

9.  A general HPLC-UV method for the quantitative determination of curcumin analogues containing the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore in rat biomatrices.

Authors:  Ravi Shankar Prasad Singh; Umashankar Das; Jonathan R Dimmock; Jane Alcorn
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-09-20       Impact factor: 3.205

10.  ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.

Authors:  Tian Chen; Radhia Benmohamed; Jinho Kim; Karen Smith; Daniel Amante; Richard I Morimoto; Donald R Kirsch; Robert J Ferrante; Richard B Silverman
Journal:  J Med Chem       Date:  2011-12-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.